IntraCoronary Treatment With Integrilin [eptifibatide] To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial

Trial Profile

IntraCoronary Treatment With Integrilin [eptifibatide] To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2012

At a glance

  • Drugs Eptifibatide (Primary)
  • Indications Coronary thrombosis
  • Focus Therapeutic Use
  • Acronyms IC-TITAN
  • Most Recent Events

    • 12 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top